-
公开(公告)号：US20240307384A1
公开(公告)日：2024-09-19
申请号：US18593518
申请日：2024-03-01
申请人： CalciMedica, Inc.
发明人： Gonul VELICELEBI , Kenneth STAUDERMAN , Michael DUNN , Jack ROOS
IPC分类号： A61K31/497 , A61K31/415 , A61K31/4155 , A61K31/421 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/485 , A61K31/506 , A61K45/06 , A61P1/18 , C07D401/04 , C07D405/04 , C07D413/14 , C07D417/10 , C07D417/14 , C07D491/04
CPC分类号： A61K31/497 , A61K31/415 , A61K31/4155 , A61K31/421 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/485 , A61K31/506 , A61K45/06 , A61P1/18 , C07D401/04 , C07D405/04 , C07D413/14 , C07D417/10 , C07D417/14 , C07D491/04 , Y02A50/30
摘要： Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
-
公开(公告)号：US20240010638A1
公开(公告)日：2024-01-11
申请号：US18252695
申请日：2020-11-13
申请人： CalciMedica, Inc.
发明人： Kenneth STAUDERMAN , Michael DUNN , Kay OLMSTEAD
IPC分类号： C07D405/04
CPC分类号： C07D405/04
摘要： Provided herein is an improved synthetic method for the production of CRAC channel inhibitors. The synthetic method provides a method for producing highly pure CRAC channel inhibitors for clinical testing.
-
公开(公告)号：US20220056053A1
公开(公告)日：2022-02-24
申请号：US17519239
申请日：2021-11-04
申请人： CalciMedica, Inc.
IPC分类号： C07F5/02 , C07D405/04 , C07C45/63
摘要： A convergent synthetic method for the production of CRAC channel inhibitors is described herein. The synthetic method provides a method for producing highly pure CRAC channel inhibitors for clinical testing.
-
公开(公告)号：US20200368228A1
公开(公告)日：2020-11-26
申请号：US16988508
申请日：2020-08-07
申请人： CalciMedica, Inc.
发明人： Gonul VELICELEBI , Kenneth STAUDERMAN , Michael DUNN , Jack ROOS
IPC分类号： A61K31/497 , A61K45/06 , A61K31/415 , A61K31/427 , A61K31/485 , C07D405/04 , C07D417/14 , A61K31/444 , A61K31/4155 , A61K31/506 , C07D401/04 , A61K31/421 , C07D417/10 , A61K31/4439 , C07D491/04 , C07D413/14 , A61P1/18
摘要： Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
-
公开(公告)号：US20220000863A1
公开(公告)日：2022-01-06
申请号：US17472422
申请日：2021-09-10
申请人： CalciMedica, Inc.
发明人： Gonul VELICELEBI , Kenneth STAUDERMAN , Michael DUNN , Jack ROOS
IPC分类号： A61K31/497 , A61K45/06 , A61K31/415 , A61K31/427 , A61K31/485 , C07D405/04 , C07D417/14 , A61K31/444 , A61K31/4155 , A61K31/506 , C07D401/04 , A61K31/421 , C07D417/10 , A61K31/4439 , C07D491/04 , C07D413/14 , A61P1/18
摘要： Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
-
公开(公告)号：US20210038597A1
公开(公告)日：2021-02-11
申请号：US17077818
申请日：2020-10-22
申请人： CalciMedica, Inc.
发明人： Gonul VELICELEBI , Kenneth STAUDERMAN , Michael DUNN , Jack ROOS
IPC分类号： A61K31/497 , A61K31/415 , A61K31/427 , A61K31/485 , C07D405/04 , C07D417/14 , A61K31/444 , A61K31/4155 , A61K31/506 , C07D401/04 , A61K31/421 , C07D417/10 , A61K31/4439 , C07D491/04 , C07D413/14 , A61P1/18 , A61K45/06
摘要： Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
-
公开(公告)号：US20230226058A1
公开(公告)日：2023-07-20
申请号：US18056973
申请日：2022-11-18
申请人： CalciMedica, Inc.
IPC分类号： A61K31/506 , A61K31/436 , A61P13/12
CPC分类号： A61K31/506 , A61K31/436 , A61P13/12
摘要： Compositions and methods related to the treatment of acute kidney injury (AKI) through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to reduce inflammatory responses that may lead to AKI, or the progression of AKI to CKD.
-
公开(公告)号：US20220265645A1
公开(公告)日：2022-08-25
申请号：US17203547
申请日：2021-03-16
申请人： CalciMedica, Inc.
发明人： Gonul VELICELEBI , Kenneth STAUDERMAN , Michael DUNN , Jack ROOS
IPC分类号： A61K31/497 , A61K45/06 , A61K31/415 , A61K31/427 , A61K31/485 , C07D405/04 , C07D417/14 , A61K31/444 , A61K31/4155 , A61K31/506 , C07D401/04 , A61K31/421 , C07D417/10 , A61K31/4439 , C07D491/04 , C07D413/14 , A61P1/18
摘要： Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may he used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
-
公开(公告)号：US20200253966A1
公开(公告)日：2020-08-13
申请号：US16481380
申请日：2018-01-26
申请人： CalciMedica, Inc.
IPC分类号： A61K31/497 , A61K47/32 , A61K47/28 , A61K47/26 , A61K47/10 , A61K47/14 , A61K9/00 , A61K9/107 , A61K9/19
摘要： Provided herein are pharmaceutical compositions, such as emulsions and nanosuspensions, comprising a CRAC channel inhibitor. Also provided herein are methods of treating pancreatitis, viral infections, stroke, traumatic brain injury, fibrosis, inflammation, and autoimmune diseases by administering such pharmaceutical compositions.
-
10.发明申请公开(公告)号：US20180235959A1
公开(公告)日：2018-08-23
申请号：US15751098
申请日：2016-08-05
IPC分类号： A61K31/497 , A61K31/44 , A61K31/427 , A61K31/415 , A61P7/00
摘要： Described herein are methods of treatment of stroke and traumatic brain injury comprising administration of a CRAC channel inhibitor.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.019 秒)
